Skip to search formSkip to main contentSkip to account menu

Prexasertib

Known as: 2-Pyrazinecarbonitrile, 5-((5-(2-(3-Aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-yl)amino)- 
An inhibitor of checkpoint kinase 1 (chk1) with potential antineoplastic activity. Upon administration, prexasertib selectively binds to chk1… 
National Institutes of Health

Related topics

Related topics

2 relations

Narrower (1)

LY2606368
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Abstract 2535: Enhanced gene expression of replication fork and other E2F targets genes is associated with sensitivity and, paradoxically, also with acquired drug resistance, to the Chk1 inhibitor…
2018
2018
Prexasertib Shows Activity in Phase II Study of High-Grade Serous Ovarian Carcinoma
The novel agent prexasertib showed promising activity and was reasonably well tolerated in a phase II study of high-grade… 
2017
2017
The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models 1 of Human Neuroblastoma 2 Running Title : Prexasertib induces regression of neuroblastoma models 3
  • 2017
  • Corpus ID: 207774016
47 Purpose: Checkpoint kinase 1 (CHK1) is a key regulator of the DNA damage response and a 48 mediator of replication stress… 
2017
2017
Prexasertib. Checkpoint kinase 1 (Chk1) inhibitor, treatment of advanced or metastatic cancer
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)